Atharva Karulkar
YOU?
Author Swipe
View article: Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.
Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India. Open
Background : Talicabtagene autoleucel (Tali-cel), a second-generation, humanized CAR-T cell therapy targeting CD19, was approved in India in October 2023 for the treatment of relapsed or refractory (r/r) B-cell malignancies. This report pr…
View article: Development of a Novel Humanized BCMA-Directed CAR for Multiple Myeloma: Robust Activity and Low Toxicity in Preclinical Studies
Development of a Novel Humanized BCMA-Directed CAR for Multiple Myeloma: Robust Activity and Low Toxicity in Preclinical Studies Open
Background: Chimeric antigen receptor T (CAR-T) cell therapies targeting B cell maturation antigen (BCMA) have emerged as a promising intervention for relapsed/refractory multiple myeloma (r/r MM). However, challenges such as treatment-rel…
View article: Data from The Th9 Axis Reduces the Oxidative Stress and Promotes the Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma Patients
Data from The Th9 Axis Reduces the Oxidative Stress and Promotes the Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma Patients Open
Immune dysfunction is critical in pathogenesis of cutaneous T-cell lymphoma (CTCL). Few studies have reported abnormal cytokine profile and dysregulated T-cell functions during the onset and progression of certain types of lymphoma. Howeve…
View article: Supplementary Table 1 from The Th9 Axis Reduces the Oxidative Stress and Promotes the Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma Patients
Supplementary Table 1 from The Th9 Axis Reduces the Oxidative Stress and Promotes the Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma Patients Open
Supplementary table S1: Follow-up patient's clinical details
View article: Data from The Th9 Axis Reduces the Oxidative Stress and Promotes the Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma Patients
Data from The Th9 Axis Reduces the Oxidative Stress and Promotes the Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma Patients Open
Immune dysfunction is critical in pathogenesis of cutaneous T-cell lymphoma (CTCL). Few studies have reported abnormal cytokine profile and dysregulated T-cell functions during the onset and progression of certain types of lymphoma. Howeve…
View article: Supplementary Table 1 from The Th9 Axis Reduces the Oxidative Stress and Promotes the Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma Patients
Supplementary Table 1 from The Th9 Axis Reduces the Oxidative Stress and Promotes the Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma Patients Open
Supplementary table S1: Follow-up patient's clinical details
View article: Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation
Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation Open
Chimeric antigen receptor T cell (CAR-T) therapy demonstrated remarkable success in long-term remission of cancers and other autoimmune diseases. Currently, six products (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti) are app…
View article: Transcriptional fluctuations govern the serum dependent cell cycle duration heterogeneities in Mammalian cells
Transcriptional fluctuations govern the serum dependent cell cycle duration heterogeneities in Mammalian cells Open
Mammalian cells exhibit a high degree of intercellular variability in cell cycle period and phase durations. However, the factors orchestrating the cell cycle duration heterogeneities remain unclear. Herein, by combining cell cycle network…
View article: Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells Open
Recent studies have described the remarkable clinical outcome of anti-CD19 chimeric antigen receptor (CAR) T cells in treating B-cell malignancies. However, over 50% of patients develop life-threatening toxicities associated with cytokine …
View article: Corrigendum: Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells
Corrigendum: Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells Open
[This corrects the article DOI: 10.3389/fimmu.2018.03180.].
View article: Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells
Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells Open
Lymphocytes especially autologous T cells have been used for the treatment of numerous indications including cancers, autoimmune disorders and infectious diseases. Very recently, FDA approved Chimeric Antigen Receptor T cells (CAR T cells)…
View article: Hydrogel scaffold with substrate elasticity mimicking physiological-niche promotes proliferation of functional keratinocytes
Hydrogel scaffold with substrate elasticity mimicking physiological-niche promotes proliferation of functional keratinocytes Open
High numbers of autologous human primary keratinocytes (HPKs) are required for patients with burns, wounds and for gene therapy of skin disorders.